379,526 Shares in Equillium, Inc. $EQ Acquired by Aberdeen Group plc

Aberdeen Group plc acquired a new stake in Equillium, Inc. (NASDAQ:EQ) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 379,526 shares of the company’s stock, valued at approximately $543,000. Aberdeen Group plc owned about 0.64% of Equillium at the end of the most recent reporting period.

Insiders Place Their Bets

In other Equillium news, COO Christine Zedelmayer sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $1.50, for a total transaction of $150,000.00. Following the transaction, the chief operating officer owned 91,444 shares in the company, valued at approximately $137,166. This represents a 52.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders sold 150,335 shares of company stock worth $213,607. Insiders own 30.30% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on EQ. Wall Street Zen upgraded shares of Equillium from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Equillium in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus price target of $1.00.

Equillium Stock Down 4.4%

Shares of Equillium stock opened at $1.74 on Monday. The business has a 50 day moving average of $1.38 and a 200 day moving average of $1.34. Equillium, Inc. has a 52 week low of $0.27 and a 52 week high of $2.35. The company has a market cap of $105.95 million, a PE ratio of -2.81 and a beta of 1.87.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.